Re­searchers at City of Hope com­bine on­colyt­ic virus with a CAR-T to erad­i­cate sol­id tu­mors in mice

A new com­bi­na­tion of ex­ist­ing can­cer treat­ments is show­ing ear­ly signs of po­ten­tial­ly crack­ing open a new ap­proach to treat­ing sol­id tu­mors.

In pre­clin­i­cal re­search pub­lished by City of Hope, a Cal­i­for­nia-based non-prof­it, sci­en­tists ef­fec­tive­ly blend­ed CAR-T ther­a­py with an on­colyt­ic virus to erad­i­cate sol­id tu­mors in mice. The virus is ge­net­i­cal­ly en­gi­neered to en­ter the tu­mors and force them to ex­press the CD19 pro­tein, al­low­ing the CAR-T cells to at­tack.

Saul Price­man

“We came up with the idea based on the com­pat­i­ble ex­per­tise and es­sen­tial­ly with sev­er­al in­ves­ti­ga­tors at City of Hope,” Saul Price­man, se­nior au­thor of the pa­per, told End­points News. “It was al­most an idea to over­come the chal­lenges as­so­ci­at­ed with treat­ing sol­id tu­mors with CAR-T cell ther­a­py … the chal­lenge be­ing what tu­mor anti­gen to go af­ter in sol­id tu­mors and al­so what we call the im­muno­sup­pres­sive mi­croen­vi­ron­ment.”

The re­searchers are ex­pect­ing to move in­to hu­man tri­als with­in the next year and a half. Price­man added he likes to de­scribe the method as “mark and kill,” where the virus marks the tu­mor with a rec­og­niz­able tar­get for the CAR-T cells that then go in for the kill.

Nor­mal­ly used to treat blood can­cers like B cell lym­phomas and acute lym­phoblas­tic leukemia, CAR-T ther­a­py has made sig­nif­i­cant head­way since net­ting its first FDA ap­proval back in late 2017. The suc­cess seen in these can­cers hasn’t trans­lat­ed in­to sol­id tu­mors as of yet giv­en that find­ing re­cep­tors on the sur­faces of those cells is much more chal­leng­ing and can lead to un­want­ed tox­i­c­i­ties.

By com­bin­ing CAR-T with a virus that es­sen­tial­ly com­pels the tu­mors in­to ex­press­ing a re­cep­tor like CD19, how­ev­er, Price­man hopes this con­cept can be a game-chang­er. Specif­i­cal­ly in the mouse tri­als, Price­man and his team showed the virus was able to ex­press CD19 in triple-neg­a­tive breast can­cer, as well as in pan­cre­at­ic, prostate, ovar­i­an, and head and neck can­cer, as well as brain tu­mor cells.

On­colyt­ic virus­es have had marked­ly less suc­cess when used on their own to treat can­cers, ac­cord­ing to pa­per co-au­thor An­tho­ny Park, large­ly be­cause the im­mune sys­tem can de­vel­op a re­sis­tance. They’ve al­so nev­er been test­ed clin­i­cal­ly, but with CAR-T’s safe­ty pro­file al­ready well-known, the team is ex­pect­ing pos­i­tive re­sults.

When used alone, the on­colyt­ic virus “will in­duce an en­doge­nous im­mune re­sponse, which could be ben­e­fi­cial for tar­get­ing tu­mors, but it can al­so be detri­men­tal to the virus ac­tiv­i­ty be­cause the im­mune sys­tem can rec­og­nize the virus to not on­ly show the tu­mor cells but al­so get rid of the virus,” Park said.

Ezra Co­hen

City of Hope’s re­sults have al­ready im­pressed some out­side ex­perts, name­ly Ezra Co­hen, the chief of UC San Diego’s hema­tol­ogy-on­col­o­gy di­vi­sion. Co­hen, who him­self is re­search­ing a sim­i­lar com­bi­na­tion us­ing ROR1-tar­get­ing CAR-T cells, said City of Hope used a “clever ap­proach” and found an added bonus in the study when the virus prop­a­gat­ed in­to oth­er tu­mor cells af­ter the orig­i­nal­ly-in­fect­ed cells died off.

That could sug­gest wide­spread ef­fi­ca­cy even if the on­colyt­ic virus doesn’t man­age to in­fect every sin­gle tu­mor cell.

“You’ve got this ham­mer, which has been suc­cess­ful in hema­to­log­i­cal dis­eases, but you can’t use it for all the pa­tients with sol­id tu­mors be­cause you can’t see the nail,” Co­hen said. “But what City of Hope did is they put the nail in­to cells that they want­ed, and now all of a sud­den you can use that ham­mer and it be­comes ef­fec­tive.”

The biggest chal­lenge mov­ing for­ward will be how well the ex­per­i­ments in mice can trans­late in­to hu­mans. Some ex­per­i­men­tal CAR-T ther­a­pies have failed at this stage be­fore, Co­hen said, as get­ting the treat­ment to hone in on the tu­mor when it’s not di­rect­ly in­ject­ed in­to its cells — some­thing that’s not al­ways pos­si­ble in hu­mans with metasta­t­ic can­cers — is im­mense­ly dif­fi­cult.

But Price­man is con­fi­dent in the ex­per­tise of the City of Hope team, not­ing that the in­sti­tu­tion has 30 ac­tive Phase I clin­i­cal tri­als with CAR-T cells in a range of dis­eases.

“One of the beau­ties of City of Hope is we’ve done this a num­ber of times,” Price­man said. “Clin­i­cal trans­la­tion of a CAR-T cell is some­thing we have a wide ex­per­tise in, and we’ve al­so grow­ing ex­per­tise in on­colyt­ic virus­es.”

So­cial: Michael Dominguez, Shut­ter­stock

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

Stéphane Bancel, Moderna CEO

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

Even as public health officials remain guarded about their comments on the likelihood Omicron will escape the reach of the currently approved Covid-19 vaccines, there’s growing scientific consensus that we’re facing a variant that threatens to overwhelm the vaccine barricades that have been erected.

Stéphane Bancel, the CEO of Moderna, one of the leading mRNA players whose quick vault into the markets with a highly effective vaccine created an instant multibillion-dollar market, added his voice to the rising chorus early Tuesday. According to Bancel, there will be a significant drop in efficacy when the average immune system is confronted by Omicron. The only question now is: How much?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

In another setback for Biogen, the big biotech lost its appeal to revive a patent for the once-blockbuster drug Tecfidera, marking a likely conclusion to the case.

The US Court of Appeals for the Federal Circuit issued the ruling Tuesday morning, saying Biogen failed to satisfy the “written description” requirement for patent law. As a result, Mylan-turned-Viatris will be able to sell its multiple sclerosis generic without fear of infringement and Biogen will have to find a new revenue driver elsewhere.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

Philip Dormitzer, new GSK global head of vaccines R&D

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.

Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

In­tro­duc­ing End­points Stu­dio, a new way to ad­ver­tise with End­points-craft­ed brand­ing cam­paigns

Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising business has too. Endpoints advertising partners support the mission and engage their desired audiences through announcements on our email and web platforms, brand recognition in our event coverage and sponsorships of Endpoints daily and weekly reports.

Tillman Gerngross (Adagio)

Till­man Gern­gross on Omi­cron: 'It is a grim sit­u­a­tion...we’re go­ing to see a sig­nif­i­cant drop in vac­cine ef­fi­ca­cy'

Tillman Gerngross, the rarely shy Dartmouth professor, biotech entrepreneur and antibody expert, has been warning for over a year that the virus behind Covid-19 would likely continue to mutate, potentially in ways that avoid immunity from infection and the best defenses scientists developed. He spun out a company, Adagio, to build a universal antibody, one that could snuff out any potential mutation.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

Mar­ket­ingRx roundup: Ab­b­Vie’s Hu­mi­ra TV turns fo­cus to HS skin con­di­tion; Sanofi amps par­ent­ing pol­i­cy

After years as the top spending pharma TV advertiser, AbbVie’s Humira brand finally downshifted earlier this year, ceding much of its marketing budget to up-and-coming sibling meds Skyrizi and Rinvoq. However, now Humira is back on TV with ads for another condition — Hidradenitis suppurativa (HS).

The chronic and painful skin condition results in lumps and abscesses caused by inflammation or infection of sweat glands, most often in the armpits or groin. Humira was first approved to treat HS in 2015 and remains the only FDA-approved drug for the condition. Two TV ads both note more than 30,000 people with HS have been prescribed Humira.

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

Barely a month after disappointing data shattered hopes for a major label expansion for the GI tumor drug Qinlock, Deciphera is making a major pivot — scrapping development plans for that drug and discarding another while it hunkers down and focuses on two remaining drugs in the pipeline.

As a result, 140 of its staffers will be laid off.

The restructuring, which claims the equivalent of 35% of its total workforce, will take place across all departments including commercial, R&D as well as general and administrative support functions, Deciphera said, as it looks to streamline Qinlock-related commercial operations in the US while concentrating only on a “select number of key European markets.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.